Search

Author/Creator Schulze, H.

7. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Issue 11 (7th October 2016)

Authors:
Stallmach, A.; Langbein, C.; Atreya, R.; Bruns, T.; Dignass, A.; Ende, K.; Hampe, J.; Hartmann, F.; Neurath, M. F.; Maul, J.; Preiss, J. C.; Schmelz, R.; Siegmund, B.; Schulze, H.; Teich, N.; von Arnim, U.; Baumgart, D. C.; Schmidt, C.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 44:Issue 11/12(2016)
Page Start:
1199
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Issue 11 (7th October 2016)

Authors:
Stallmach, A.; Langbein, C.; Atreya, R.; Bruns, T.; Dignass, A.; Ende, K.; Hampe, J.; Hartmann, F.; Neurath, M. F.; Maul, J.; Preiss, J. C.; Schmelz, R.; Siegmund, B.; Schulze, H.; Teich, N.; von Arnim, U.; Baumgart, D. C.; Schmidt, C.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 44:Issue 11/12(2016)
Page Start:
1199
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗